New CMC Process R&D center will add peptide and oligo-intermediate capabilities, expand analytical and formulation labs and target completion by September 2026. Sai Life Sciences plans to build a 100,000-sq-ft CMC Process R&D center at its integrated R&D campus in Hyderabad, aiming to double its process R&D capacity by September 2026. The project adds dedicated…
Sai adds dedicated veterinary-API capacity in India as part of a broader animal-health buildout
Sai Life Sciences, a Hyderabad-based contract research, development, and manufacturing organization (CRDMO) has opened Unit VI, a dedicated veterinary-API facility in Bidar, India, adjacent to the company’s flagship API site. The company positions the site to supply animal-health sponsors and contract customers, citing rising demand for veterinary medicines and the need for dedicated manufacturing capacity…
Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in…